If you asked most people where a French MedTech company might set up its first U.S. office, they’d probably say Boston, San Diego, or maybe Silicon Valley. But E-Scopics, an Aix-en-Provence-based ultrasound company focused on point-of-care liver health innovation, chose St. Louis instead, and that decision says a lot about where the next wave of healthcare breakthroughs is taking root.
A Fresh Take on Liver Health
At the center of E-Scopics’ work is a deceptively simple idea: give primary-care doctors the tools to check liver health during a routine appointment. Their device, called HepatoScope™, is a point-of-care ultrasound tool to quickly measure MASLD (fatty liver) and MASH (fibrosis) that can be used right in the exam room no specialist referral, no waiting months for results.
It’s designed to help physicians screen for liver disease early, before it becomes critical. In a country where liver disease will impact over 40% of the population in a few years typically goes undiagnosed; that’s a big deal.
“This is a simple, accessible way to more accurately determine the health of your liver than legacy methods,” said Jim Howard, E-Scopics’ Senior Vice President of U.S. Commercial Operations. “We’re bringing transparency into liver care at the point of first contact, which helps close a major care gap and addresses costly comorbidities.”
Why St. Louis?
For Howard and the E-Scopics team, choosing St. Louis wasn’t just a business move; it was a strategic partnership decision.
“The decision to put our commercial headquarters here was driven by the health-system concentration, the city’s central location, and the fact that several of the highest-prevalence regions for liver disease are in the southern half of the United States,” Howard explained. “St. Louis puts us right in the middle of where this innovation and access are urgently needed.”
But geography was only part of the story. The team found something deeper in St. Louis’s MedTech community, a spirit of collaboration that’s not always easy to find in competitive health-tech hubs.
The Power of an Ecosystem
Through BioSTL, E-Scopics was able to tap into a network of innovators, healthcare systems, and civic leaders who genuinely want to help new ideas take root.
“I’ve worked in the BioSTL environment multiple times, and their support made a real difference,” Howard said. “From providing office space to making critical introductions in population health, FQHC’s, rural health, and research, the collaborative approach here makes it easier to innovate and bring solutions into clinical practice at scale.”
That sense of partnership, rather than competition, was a major draw. It gave E-Scopics the momentum to move faster and build connections that might have taken years elsewhere.
Looking Ahead: Building a New Model for Liver Care
E-Scopics sees its St. Louis base as more than a launchpad. It’s a long-term investment in learning from U.S. health-system partners and co-creating a new model of liver care, one that starts in the primary-care office instead of the hospital.
“We’re here to enable earlier detection of liver disease through a software-centric approach patient stratification with rapid steatosis and liver stiffness measurements,” Howard said. “We’re here to learn from our partners and hold hands with them as we lead this forward with new therapies finally on the market. No one has tackled liver disease at this scale in primary care before.”
As the company settles into the city’s growing health innovation corridor, St. Louis adds another chapter to its story as a place where global MedTech meets Midwest collaboration and where the next generation of healthcare breakthroughs can take shape.